Glial Progenitors

Online Inquiry

For Research Use Only. Not For Clinical Use.

Contact Us

  • Email:

Glial Progenitors

Over the years, Creative Biolabs has been accumulated further experience in STEMOD™ neuroscience ex vivo models. We are fully dedicated to providing a full range of research services, such as the astrocyte differentiation service for our global customers.

Glial Progenitors

Glial cells are derived from stem cells that mature through many stages of development to generate differentiated astrocytes and oligodendrocytes. Glial cells can be formed from the induced neuroectoderm, and the initially formed glial precursors generated in the ventricular or subventricular zone migrate to their final destinations using cues similar to those used by neurons. Glial progenitor cells (GPCs) are present throughout the parenchyma of the central nervous system (CNS) in the brain and arise from neural stem cells of the ventricular subependymal. GPCs numerically represent an extremely large cell pool. GPCs likely divide at a slow rate in-situ to provide cellular replacement of glial populations throughout life, including astrocytes, microglial phenotypes, and oligodendrocytes.

Localization of neural stem cells and the widespread localization of glial progenitors.

Role in the Nervous System

Glial cells and their progenitors play multiple roles helping to alleviate neurological defects after brain injury, not the least by promoting axonal and neuronal function and fostering neuronal survival. GPCs, as the source of oligodendrocytes, are responsible for remyelination in the demyelinated adult CNS. Proliferating glial cells within the injury site provide a local source of cells for repair, including replacing neurons. This precursor cell can be surviving in the damaged environment and migrate into the lesioned site to participate in the remyelination of damaged tissue.

GPC-based Treatment for CNS Diseases

In recent years, it has become more and more clear that a number of neurodegenerative and psychiatric disorders are causally linked to glial dysfunction, besides the glial disorders of oligodendrocyte loss and myelin failures. For glial cell-related diseases, modulating the glial reparative response by either transplantation or mobilization of allogeneic GPCs may be a logical intervention for obtaining therapeutic improvement. For example, progressive MS might comprise an especially attractive target for a glial replacement since oligodendrocyte engagement with otherwise denuded axons might serve to preserve neuronal viability even in the absence of remyelination. The delivery of GPCs into the demyelinated brain may thus offer tangible benefits by oligodendroglial replacement and axonal engagement perse, as well as by myelin repair.

Glial progenitor cell sources, phenotypes, and clinical targets. Fig.2 Glial progenitor cell sources, phenotypes, and clinical targets. (Goldman, 2017)

Services at Creative Biolabs

GPCs derived from pluripotent stem cells (PSCs), including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), are considered as an attractive in vitro model for studying the pathology of CNS disorders for the identification of novel drug targets and development of therapeutic drugs. As an experienced expert in STEMOD™ models, Creative Biolabs provides comprehensive custom services for neural differentiation from the glial progenitors to effectively support your neuroscience research. Our diverse STEMOD™ ex vivo model offers an advanced platform for a series of custom differentiation services, including but not limited to:

Thanks to a longstanding presence in the field of neuroscience ex vivo models, Creative Biolabs is the right partner to navigate the astrocyte differentiation challenges. We are pleased to provide support for any of your questions. What you need to do is feel free to send us your specific demands. Our professional scientist will reply to you as soon as possible.

Reference

  1. Goldman, S. A. Progenitor cell-based treatment of glial disease. Progress in brain research. 2017, 231, 165-189.

For Research Use Only. Not For Clinical Use.